000 01185 a2200349 4500
005 20250513061100.0
264 0 _c19930211
008 199302s 0 0 eng d
022 _a0025-7125
024 7 _a10.1016/s0025-7125(16)30278-4
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aCaroff, S N
245 0 0 _aNeuroleptic malignant syndrome.
_h[electronic resource]
260 _bThe Medical clinics of North America
_cJan 1993
300 _a185-202 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAge Factors
650 0 4 _aAntipsychotic Agents
_xadverse effects
650 0 4 _aDantrolene
_xtherapeutic use
650 0 4 _aDiagnosis, Differential
650 0 4 _aDopamine Agents
_xtherapeutic use
650 0 4 _aElectric Stimulation Therapy
650 0 4 _aHumans
650 0 4 _aNeuroleptic Malignant Syndrome
_xdiagnosis
650 0 4 _aPrognosis
650 0 4 _aRecurrence
650 0 4 _aRisk Factors
650 0 4 _aSex Factors
700 1 _aMann, S C
773 0 _tThe Medical clinics of North America
_gvol. 77
_gno. 1
_gp. 185-202
856 4 0 _uhttps://doi.org/10.1016/s0025-7125(16)30278-4
_zAvailable from publisher's website
999 _c8092816
_d8092816